pre-IPO PHARMA

COMPANY OVERVIEW

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.


LOCATION

  • Shanghai, None, China
  • Princeton, NJ, USA

  • THERAPEUTIC AREAS

  • Cardiovascular Disease
  • Oncology

  • WEBSITE

    https://www.lianbio.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    perceptive-advisors


    PRESS RELEASES


    Oct 20, 2021

    LianBio Announces Launch of Initial Public Offering


    Oct 13, 2021

    LianBio Appoints Jesse Wu to Board of Directors


    Oct 12, 2021

    LianBio Appoints Susan Silbermann to Board of Directors


    Oct 4, 2021

    LianBio Appoints Michael Humphries as Chief Scientific Advisor


    Aug 25, 2021

    BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors


    For More Press Releases


    Google Analytics Alternative